H1 secures $40M from CVS, proving SaaS startups can still attract investment
Quick Answer
H1 has successfully secured $40 million in funding from CVS, demonstrating that SaaS startups can still attract significant investment.
Quick Take
H1 has successfully secured $40 million in funding from CVS, demonstrating that SaaS startups can still attract significant investment. CEO Ariel Katz emphasizes that while AI can replicate workflow SaaS, it cannot duplicate H1's unique doctor data, setting the company apart in the competitive landscape.
Key Points
- H1 raised $40 million from CVS for its unique doctor data platform.
- CEO Ariel Katz highlights the limitations of AI in replicating H1's offerings.
- The funding showcases ongoing investor interest in innovative SaaS solutions.
- H1 differentiates itself in the market with proprietary data assets.
📖 Reader Mode
~2 min readIt’s no secret that pre-AI era startups are generally getting little love from investors now.
Ariel Katz, co-founder and CEO of a nine-year-old healthcare data platform H1, argues that not all SaaS companies should be painted with the same broad brush.
“If you’re a workflow SaaS company, you could vibe code that,” he told TechCrunch. What AI cannot easily replicate, according to Katz, is a company that is a data provider at its core.
That’s a self-serving viewpoint — H1’s entire business is built on selling detailed information about doctors to pharma companies, hospital systems, and health insurers — but it doesn’t mean he is wrong.
“I don’t worry about Claude ever doing what we do,” Katz said, referring to Anthropic’s popular AI model. He thinks that the data H1 collects on physicians globally could actually be so valuable to AI model makers that they are more likely to become customers than competitors.
CVS Health Ventures, the corporate venture capital arm of the CVS/Aetna health giant, must agree that H1 is in no danger of becoming a victim of the “SaaSocalypse.” The investor just led a $40 million round into H1.
H1 wasn’t looking to raise capital, Katz said. The startup turned cash flow and EBITDA profitable last year and is forecasting to grow over 40% this year. But the partnership with one of the largest healthcare companies in the world was hard to refuse, Katz said.
Despite the strong financial fundamentals, companies like H1 aren’t exciting for traditional VCs who are currently consumed with backing AI startups at skyrocketing valuations.
H1 was last valued at $750 million when it raised $100 million in funding led by Altimeter Capital at the height of the Covid-era tech bubble in November of 2021.
Like other companies that secured capital just before valuations plummeted in 2022, H1 has focused on becoming profitable. The startup has also grown through acquiring smaller competitors and complementary businesses.
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.
Marina Temkin is a venture capital and startups reporter at TechCrunch. Prior to joining TechCrunch, she wrote about VC for PitchBook and Venture Capital Journal. Earlier in her career, Marina was a financial analyst and earned a CFA charterholder designation.
You can contact or verify outreach from Marina by emailing marina.temkin@techcrunch.com or via encrypted message at +1 347-683-3909 on Signal.
— Originally published at techcrunch.com
Want this in your inbox every morning?
Daily brief at your local 8am — bilingual EN/中文, free.
More from TechCrunch
See more →
OpenAI launches its new family of models with GPT-5.6
OpenAI has launched GPT-5.6, featuring three models: Sol, Terra, and Luna, with Sol being 54% more token efficient for coding tasks. The models excel in cybersecurity and enterprise applications, outperforming competitors like Anthropic's Fable in benchmarks. Pricing starts at $1 for Luna and goes up to $30 for Sol per million tokens.
